Loading organizations...
§ Private Profile · San Francisco, CA, USA
Platform for breakthrough mental health research and treatment
Osmind has raised $57.0M across 3 funding rounds.
Key people at Osmind.
Osmind was founded in 2020 by Jimmy Qian (Founder) and Lucia Huang (Founder).
Osmind has raised $57.0M in total across 3 funding rounds.
Osmind is the premier platform for clinicians and researchers advancing new life-saving mental health treatments. Today, mental health disorders are one of the leading causes of death worldwide, especially among young adults, and are tied to shortening lifespans. While there have been developments in new psychiatric medications since the first FDA approval in 1954, today there is a growing movement among clinicians, patients, and researchers who are recognizing the need to accelerate new science.
The Osmind treatment platform is the first and only solution that solves specific challenges faced by neuropsychiatric clinics, spanning general psychiatry and interventional psychiatry (transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, electroconvulsive therapy). The core electronic health record (EHR) technology is precisely developed for interventional treatment workflows and designed to support a strong therapeutic alliance, including journaling tools and assistance with health plan reimbursement, which is a significant access hurdle for millions of patients.
Research from our platform is already helping to set new standards for mental health interventions. For example, in the largest published real-world analysis of ketamine infusion therapy for depression, we teamed up with Stanford University School of Medicine to share findings in the Journal of Affective Disorders (March 2022). We have multiple ongoing research studies leveraging our proprietary real-world data, including an even larger ketamine analysis leveraging machine learning to predict treatment outcomes.
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. We are backed by top investors including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.
Key people at Osmind.
Osmind is a mental health technology company that builds a specialized electronic health record (EHR) platform tailored for psychiatric and interventional psychiatry practices. Its product serves clinicians, researchers, and patients involved in advanced mental health treatments such as ketamine therapy, transcranial magnetic stimulation (TMS), psychedelic-assisted psychotherapy, and other breakthrough modalities. Osmind’s platform streamlines clinical workflows, automates administrative tasks like billing and insurance prior authorization, and enhances patient engagement through a dedicated mobile app that supports mood tracking, automated follow-ups, and out-of-network insurance claim submissions. By combining clinical care with real-world data collection, Osmind advances mental health research and treatment outcomes, positioning itself as a critical enabler in the evolving mental health ecosystem[1][4][5][7][8].
Founded as a Public Benefit Corporation, Osmind emerged from the need to improve mental health treatment and research by addressing the limitations of traditional EHR systems that were not optimized for psychiatric care. The founders, with backgrounds in psychiatry, technology, and healthcare innovation, identified the gap in specialized tools for interventional psychiatry and breakthrough treatments. Early traction came from building a system that not only improved practice efficiency but also aggregated anonymized patient data to generate new clinical insights, exemplified by one of the largest real-world analyses of ketamine therapy for depression. This dual focus on clinical utility and research impact has shaped Osmind’s evolution and growth[1][5].
Osmind rides the growing trend of digital transformation in mental health care, particularly the rise of interventional psychiatry and psychedelic-assisted therapies. The timing is critical as mental health disorders gain increased recognition and demand for innovative, evidence-based treatments grows. Market forces such as expanded insurance coverage for novel therapies, regulatory approvals (e.g., SPRAVATO®), and the need for scalable, data-driven care models favor Osmind’s integrated platform. By bridging clinical care with research data, Osmind influences the broader ecosystem by enabling precision psychiatry, improving patient outcomes, and accelerating the adoption of breakthrough treatments across the mental health field[4][5][7][8].
Osmind is well-positioned to expand its influence as mental health care increasingly embraces technology-enabled, measurement-based, and personalized treatment approaches. Future growth will likely involve deeper integration with emerging therapies, expanded data analytics capabilities, and broader adoption by psychiatric practices globally. Trends such as AI-driven clinical decision support, telepsychiatry, and value-based care models will shape Osmind’s journey. Its role as both a clinical tool and research platform suggests it will continue to be a key player in advancing mental health treatment standards and improving patient outcomes worldwide[5][7][8].
Osmind was founded in 2020 by Jimmy Qian (Founder) and Lucia Huang (Founder).
Osmind has raised $57.0M in total across 3 funding rounds.
Osmind's investors include Justin Kao, 11, 2xN, Abstract Ventures, Kevin Hartz, Accel, Addition, Alumni Ventures, Amplo, Andreessen Horowitz, Angel investor, Atomic.
Osmind has raised $57.0M across 3 funding rounds. Most recently, it raised $40.0M Series B in May 2022.
